Integra LifeSciences Holdings (IART) Is At $57.38 Formed Wedge; Last Week Intuitive Surgical, Inc. (ISRG) Analysts

Integra LifeSciences Holdings Corporation (IART) formed wedge up with $59.68 target or 4.00% above today’s $57.38 share price. Integra LifeSciences Holdings Corporation (IART) has $4.50B valuation. The stock increased 1.90% or $1.07 during the last trading session, reaching $57.38. About 1.03 million shares traded or 103.49% up from the average. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 32.67% since March 19, 2017 and is uptrending. It has outperformed by 15.97% the S&P500.

Among 20 analysts covering Intuitive Surgical Inc (NASDAQ:ISRG), 14 have Buy rating, 1 Sell and 5 Hold. Therefore 70% are positive. Intuitive Surgical Inc had 68 analyst reports since July 22, 2015 according to SRatingsIntel. On Wednesday, July 20 the stock rating was maintained by Wedbush with “Outperform”. The firm earned “Buy” rating on Tuesday, February 6 by Citigroup. Cantor Fitzgerald maintained it with “Buy” rating and $490.0 target in Tuesday, February 20 report. Piper Jaffray maintained it with “Hold” rating and $290.0 target in Thursday, October 19 report. The firm has “Buy” rating given on Thursday, July 20 by Stifel Nicolaus. The firm has “Neutral” rating by Goldman Sachs given on Thursday, June 2. The firm earned “Outperform” rating on Thursday, January 14 by Leerink Swann. The company was maintained on Friday, May 26 by Canaccord Genuity. J.P. Morgan maintained the shares of ISRG in report on Friday, July 21 with “Buy” rating. Barclays Capital maintained it with “Overweight” rating and $750 target in Wednesday, July 20 report. See Intuitive Surgical, Inc. (NASDAQ:ISRG) latest ratings:

20/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $490.0 Maintain
06/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $531 New Target: $507 Maintain
26/01/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $450 New Target: $500 Maintain
26/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $490.0 Maintain
26/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $410.0 Maintain
25/01/2018 Broker: Piper Jaffray Rating: Hold New Target: $405.0 Maintain
25/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $480.0 Maintain
18/01/2018 Broker: Leerink Swann Rating: Buy New Target: $475.0 Maintain
10/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $410.0 Maintain
02/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $380.0 Maintain

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.31, from 1.29 in 2017Q2. It worsened, as 22 investors sold Integra LifeSciences Holdings Corporation shares while 60 reduced holdings. 26 funds opened positions while 80 raised stakes. 68.21 million shares or 2.93% more from 66.26 million shares in 2017Q2 were reported. Amalgamated Natl Bank owns 8,743 shares. Numeric Invsts Limited Company accumulated 0% or 9,300 shares. Invesco Limited holds 1.58M shares. Broadfin Cap Limited holds 0.59% or 78,500 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,752 shares in its portfolio. Westfield Management Limited Partnership reported 0.33% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Koch Indus stated it has 0.15% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Principal Gp stated it has 0.02% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Renaissance Llc holds 0.01% or 210,900 shares. Rmb Capital Ltd Liability Com stated it has 0.13% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Vanguard invested in 5.68M shares or 0.01% of the stock. Envestnet Asset Mngmt Inc reported 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Deutsche Commercial Bank Ag holds 255,590 shares or 0.01% of its portfolio. 293,774 were accumulated by Schwab Charles Management. Atlanta Capital Mngmt L L C holds 0.2% in Integra LifeSciences Holdings Corporation (NASDAQ:IART) or 688,765 shares.

Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on April, 25. They expect $0.49 EPS, up 25.64% or $0.10 from last year’s $0.39 per share. IART’s profit will be $38.46M for 29.28 P/E if the $0.49 EPS becomes a reality. After $0.64 actual EPS reported by Integra LifeSciences Holdings Corporation for the previous quarter, Wall Street now forecasts -23.44% negative EPS growth.

Among 15 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Integra Lifesciences Holdings Corp. has $96 highest and $44.0 lowest target. $60.67’s average target is 5.73% above currents $57.38 stock price. Integra Lifesciences Holdings Corp. had 36 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, May 30 by Jefferies. The rating was maintained by RBC Capital Markets on Friday, January 13 with “Sector Perform”. Lake Street maintained the shares of IART in report on Thursday, April 28 with “Hold” rating. The rating was maintained by Barclays Capital on Thursday, June 2 with “Equalweight”. The company was maintained on Wednesday, February 28 by JMP Securities. The firm has “Buy” rating given on Monday, September 21 by Bank of America. The stock has “Buy” rating by UBS on Wednesday, June 7. The company was downgraded on Monday, August 24 by Zacks. Oppenheimer maintained it with “Buy” rating and $6000 target in Friday, June 23 report. The firm has “Hold” rating by Lake Street given on Wednesday, August 26.

Investors sentiment increased to 12.48 in Q3 2017. Its up 11.44, from 1.04 in 2017Q2. It is positive, as 35 investors sold Intuitive Surgical, Inc. shares while 190 reduced holdings. 63 funds opened positions while 170 raised stakes. 36.20 million shares or 0.41% more from 36.05 million shares in 2017Q2 were reported. Commercial Bank Of The West has invested 0.11% of its portfolio in Intuitive Surgical, Inc. (NASDAQ:ISRG). Metropolitan Life Insur stated it has 0.13% of its portfolio in Intuitive Surgical, Inc. (NASDAQ:ISRG). Cibc Asset Mngmt Inc holds 0.04% or 5,568 shares in its portfolio. Joel Isaacson And Com Limited Liability Corp holds 0.06% in Intuitive Surgical, Inc. (NASDAQ:ISRG) or 300 shares. Commonwealth Bank & Trust Of Aus stated it has 920 shares or 0.01% of all its holdings. Connor Clark & Lunn Management Limited invested in 0.01% or 1,725 shares. Trust Of Virginia Va holds 0.05% of its portfolio in Intuitive Surgical, Inc. (NASDAQ:ISRG) for 330 shares. Carroll Financial Associate Incorporated holds 6 shares or 0% of its portfolio. Biondo Invest Advisors Limited Liability Co owns 8.46% invested in Intuitive Surgical, Inc. (NASDAQ:ISRG) for 88,194 shares. Moreover, Johnson Investment Counsel Incorporated has 0.03% invested in Intuitive Surgical, Inc. (NASDAQ:ISRG) for 1,080 shares. Parkside Finance State Bank Trust has 0.01% invested in Intuitive Surgical, Inc. (NASDAQ:ISRG). Baillie Gifford & owns 1.13 million shares. Wellington Management Grp Inc Limited Liability Partnership invested in 0.07% or 286,735 shares. Pittenger & Anderson Inc invested in 35 shares. Redmond Asset Mngmt Lc invested in 1,553 shares or 0.74% of the stock.

The stock decreased 1.38% or $6.09 during the last trading session, reaching $435.86. About 960,395 shares traded or 17.23% up from the average. Intuitive Surgical, Inc. (NASDAQ:ISRG) has risen 39.52% since March 19, 2017 and is uptrending. It has outperformed by 22.82% the S&P500.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company has market cap of $49.28 billion. The companyÂ’s da Vinci surgical System translates a surgeonÂ’s natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. It has a 76.87 P/E ratio. The Company’s da Vinci surgical system include surgeonÂ’s consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures.